Search results
Results from the WOW.Com Content Network
Acer palmatum is deciduous, with the growth habit of a shrub or small tree reaching heights of 6 to 10 m (20 to 33 ft), rarely 16 m (52 ft), reaching a mature width of 4.5 to 10 m (15 to 33 ft), [8] often growing as an understory plant in shady woodlands. It may have multiple trunks joining close to the ground.
The maples belong to the genus Acer, an important group of mainly deciduous trees and shrubs in the family Sapindaceae, which are widely cultivated throughout the temperate northern hemisphere. Some, such as Acer griseum , have ornamental bark; but most are valued in cultivation for their brilliant autumn foliage in shades of yellow, orange and ...
Acer shirasawanum, the Shirasawa maple or fullmoon maple (Japanese: オオイタヤメイゲツ, romanized: ooitayameigetsu), is a species of maple native to Japan, on central and southern Honshū (Fukushima Prefecture southwards), Shikoku, and Kyūshū.
Acer palmatum (Japanese maple) alone has over 1,000 cultivars, most selected in Japan, and many of them no longer propagated or not in cultivation in the Western world. Some delicate cultivars are usually grown in pots and rarely reach heights of more than 50–100 cm. Acer palmatum var. 'Kiyohime' as bonsai during fall abscission. This dwarf ...
During the week ending Feb. 1, nearly 8% of visits to health care providers were for influenza-like illness (a fever plus a cough or sore throat) — the highest level seen since the peak of the ...
Fourteen members of a small religious sect in Australia have been found guilty of the manslaughter of an 8-year-old girl, who died after they withheld insulin needed to treat her diabetes because ...
Fullmoon maple (Acer japonicum) Acer laevigatum seeds Japanese maple (Acer palmatum) Series Palmata. Acer amoenum (Carriere) Hara; Acer anhweiense Fang & Fang f. Acer calcaratum Gagnep. Acer campbellii Hook.f. & Thomson ex Hiern – Campbell's maple; Acer chingii Hu; Acer circinatum Pursh – vine maple; Acer confertifolium Merril & Metcalf ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.